financetom
Business
financetom
/
Business
/
Update: Target Shares Fall After Fiscal Q1 Adjusted Earnings, Revenue Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Target Shares Fall After Fiscal Q1 Adjusted Earnings, Revenue Decline
May 26, 2025 11:55 AM

02:32 PM EDT, 05/21/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.)

Target ( TGT ) shares were down nearly 5% in recent Wednesday trading after the company reported a year-over-year decline in fiscal Q1 adjusted earnings and sales, both of which also missed analysts' expectations.

The company reported fiscal Q1 adjusted earnings Wednesday of $1.30 per diluted share, down from $2.03 a year earlier.

Analysts polled by FactSet expected $1.61.

Sales for the fiscal quarter ended May 3 were $23.85 billion, down from $24.53 billion a year earlier.

Analysts surveyed by FactSet expected $24.23 billion.

For 2025, the company now expects adjusted EPS of $7.00 to $9.00 on a low-single digit decline in sales, compared to its previous projection of adjusted EPS of between $8.80 and $9.80 on net sales growth of around 1%.

Analysts polled by FactSet expect non-GAAP EPS of $8.34 on revenue of $106.67 billion.

Price: 93.43, Change: -4.69, Percent Change: -4.78

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Aug 30, 2024
Friday, Alnylam Pharmaceuticals Inc. ( ALNY ) stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was revealed in June. The data were presented at the European Society of Cardiology Congress 2024. Also Read: Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst...
Update: Market Chatter: Nvidia Considering $100 Million Investment in OpenAI
Update: Market Chatter: Nvidia Considering $100 Million Investment in OpenAI
Aug 30, 2024
07:59 AM EDT, 08/30/2024 (MT Newswires) -- (Update with company comment in third paragraph) Nvidia ( NVDA ) is considering participating in a funding round for OpenAI and has discussed investing about $100 million in the artificial intelligence startup, Bloomberg reported Friday, citing people familiar with the matter. The report said this latest funding round would value OpenAI at over...
Solar Module Company JinkoSolar's Q2 Earnings: 22% Revenue Drop, Margins Hit By Lower Average Selling Price
Solar Module Company JinkoSolar's Q2 Earnings: 22% Revenue Drop, Margins Hit By Lower Average Selling Price
Aug 30, 2024
JinkoSolar Holding Co ( JKS )  stock tanked Friday premarket after the company reported second-quarter results. The solar module manufacturer’s revenue decreased 21.6% year-over-year to $3.31 billion, missing the analyst consensus estimate of $3.91 billion. Adjusted earnings per ADS of $0.99 beat the analyst consensus estimate of $0.17. Quarterly shipments increased 36.0% Y/Y to 25,318 MW (23,822 MW for solar modules...
Leveraged Nvidia ETF issuers saw trading surge in bearish products ahead of earnings
Leveraged Nvidia ETF issuers saw trading surge in bearish products ahead of earnings
Aug 30, 2024
Aug 29 (Reuters) - Interest in leveraged exchange-traded funds that allow investors to profit when shares of Nvidia ( NVDA ) fall grew steadily ahead of the chipmaker's quarterly results, according to data from some of the companies that issued the products. Nvidia ( NVDA ), which in June eclipsed Microsoft ( MSFT ) as the world's most valuable company,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved